

# Bio-Energetic Sequencing: Commercializing the Solution to Biological Aging




The **\$1 Trillion** Opportunity to  
Transform Human Healthspan

# Aging is Not a Disease; It's a Systemic Failure Generating Every Major Disease.



Current approaches are reactive, expensive, and address symptoms, not the root cause.



# We've Moved Aging From a Biological Mystery to a Solvable Engineering Problem.



[1. Energy Systems]

[2. Cellular Clearance]


[3. Senescent Cell Removal]

[4. Regeneration]

[5. Epigenetic Maintenance]

The Bio-Energetic Sequencing Model: A **dependency-gated** protocol that systematically restores cellular maintenance. For the first time, we address the **root cause** in the **right order**.


# Built on a Decade of Converging Breakthroughs in Geroscience



Underpinned by 74 peer-reviewed sources, foundational IP, and a framework for biomarker-based regulatory endpoints.

# Competitors Are Targeting a Single Domino. We Control the Entire Cascade.

## Competitors: The Silos



Single-Target

Unsequenced

Palliative

## Our Approach: The System



**Bio-Energetic Sequencing**


Systemic

Sequenced


Regenerative

Single-target interventions fail because they ignore dependencies. You can't regenerate tissue (Phase 4) while it's suppressed by senescent cells (Phase 3). You can't clear cellular damage (Phase 2) without sufficient energy (Phase 1). **Our sequence is our moat.**


# A Multi-Channel Healthspan Ecosystem Built on a Single Core Platform



**Projected 5-Year Revenue Mix**



# A Disciplined, Phased Rollout to Capture the High-Value Market First.



0-18 Months

## Establish the Beachhead

Prove unit economics with high-net-worth individuals, generating a premium brand halo.

0 Months

18-36 Months

## Scale the Model

Achieve capital-efficient growth and reach profitability.

18 Months

36-60 Months

## Global Platform Leadership

Achieve unicorn valuation and establish market dominance.

36 Months

60 Months

# Strong Market Signals Indicate The World is Ready



## High-Value Demand

Early adopter interest from HNWIs, professional athletes, and tech executives, exemplified by figures like biohacker Ben Greenfield.



## Healthcare System Pull

Inbound interest from concierge medicine groups seeking preventative, high-value solutions.



## Regulatory Precedent

Clear pathway for biomarker-based approvals, following precedents like the FDA TAME trial for metformin, which targets aging as a treatable condition.




## World-Class Advisory

Assembled a strategic advisory board of leading geroscience researchers from institutions like the Buck Institute and veteran healthcare executives.

# A High-Margin, Capital-Efficient Model with Strong Unit Economics


## 5-Year Revenue Growth




## Key Unit Economics

	Customer Lifetime Value (LTV)	\$50,000 - \$200,000 (5-yr)
	Gross Margin	70%+
	Customer Acquisition Cost (CAC) Payback	< 12 Months

## Path to Profitability



# \$20M Series A to Execute Phase 1 and Unlock a 10x Valuation Step-Up.



## Key Milestones Unlocked



# World-Class Science Meets Proven Execution.

## Scientific & Medical Leadership



**Jane Doe, PhD**  
Chief Scientific Officer  
Former Researcher,  
Buck Institute



**John Smith, MD**  
Chief Medical Officer  
Contributor to Information  
Theory of Aging research



**Dr. Sarah Lee, PhD**  
Head of Research  
Leading expert in  
Epigenetic Clocks



**Dr. Mark Davis, MD**  
Lead Clinician  
Board-certified in  
Longevity Medicine

## Business & Operations Leadership



**Emily Chen**  
Chief Executive Officer  
Scaled [XYZ Concierge  
Clinic] to 50 locations



**David Rodriguez**  
Chief Operating Officer  
Ex-Google Health, led  
commercialization



**Anna Kim, MBA**  
Chief Financial Officer  
Experienced in  
Healthcare Investment



**Michael Brown**  
Chief Marketing Officer  
Former VP at [Major  
Healthcare Brand]

# The Ground Floor of the Healthspan Revolution.

**Seeking \$20M Series A** to become the category-defining leader in engineered healthspan.

- **Massive, Untapped Market:** Addressing the \$3T+ root cause of all major chronic diseases.
- **Defensible Scientific Moat:** A unique, dependency-gated systems model that is scientifically superior to all single-target approaches.
- **Clear Path to Profitability:** A high-margin, multi-channel business model with proven unit economics.
- **World-Class Team:** The right blend of scientific vision and operational excellence to execute the plan.

Exit Opportunities: IPO, Strategic Acquisition (Big Pharma/Biotech).  
Contact: [Name], [Email], [Phone Number].